LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
29 funds hold it · Insiders net selling
Net selling: insiders sold $22.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 6, 2026
Financial period
Q3 2026
Earnings per share
-$1.35 expected
Revenue
$891.3M expected
Estimates as of Nov 12, 2026
EPS expected
-$4.29 to -$1.70
Revenue expected
6 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 6, 2026 | $0.38est. -$1.35 | +128.12%beat | $1.30Best. $891.3M+45.85% | +28.0%from $1.02B |
| Jun 30, 2026Reported Jul 31, 2026 | -$1.97est. -$2.11 | +6.64%beat | $145.0MCompany release | +2.1%from $142.0M |
| Mar 31, 2026Reported May 1, 2026 | -$3.40est. -$3.96 | +14.08%beat | $389.0MSEC filing | +260.2%from $108.0M |
| Dec 31, 2025Reported Feb 13, 2026 | -$2.11est. -$2.64 | +20.18%beat | $678.0MAlpha Vantage | -29.1%from $956.0M |
| Sep 30, 2025Reported Nov 6, 2025 | -$0.51est. -$2.16 | +76.39%beat | $1.02BSEC filing | -45.4%from $1.86B |
| Jun 30, 2025Reported Aug 1, 2025 | -$2.13est. -$3.00 | +29.00%beat | $142.0MSEC filing | -41.1%from $241.0M |
| Mar 31, 2025Reported May 1, 2025 | -$2.52est. -$3.11 | +18.97%beat | $108.0MSEC filing | -35.3%from $167.0M |
| Dec 31, 2024Reported Feb 14, 2025 | -$2.91est. -$2.76 | -5.44%miss | $956.0MAlpha Vantage | -66.0%from $2.81B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $678.0M | $389.0M | $145.0M | $1.31B |
| Cost of what it sold | $452.0M | $955.0M | $93.0M | $318.0M |
| Gross profit | $226.0M | -$566.0M | $52.0M | $995.0M |
| What it spent | ||||
| Research and development | $775.0M | $649.0M | $651.0M | $583.0M |
| Sales and admin | $308.0M | $173.0M | $216.0M | $282.0M |
| Total operating expenses | $1.08B | $822.0M | $867.0M | $865.0M |
| What was left | ||||
| Operating profit | -$857.0M | -$1.39B | -$815.0M | $130.0M |
| Interest on debt | $8.0M | $17.0M | $17.0M | $18.0M |
| Profit before tax | -$799.0M | -$1.33B | -$767.0M | $171.0M |
| Tax | $27.0M | $9.0M | $15.0M | $9.0M |
| Net profit | -$826.0M | -$1.34B | -$782.0M | $162.0M |
| EBITDA | -$732.0M | -$1.26B | -$704.0M | $239.0M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE in Adults Aged 65 Years and Older
BullishNov 11Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
BullishNov 11Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
BullishNov 11Will Earnings And Lung Cancer Data Change Iovance Stock Narrative
NeutralNov 11How $300,000 in EWT Ends Up With $60,924 in a Single Chipmaker
BearishNov 11Is Amgen Stock Too Dependent On Six Growth Drivers?
NeutralNov 11What Is Moderna Building That Investors Should Watch?
Leans bullishNov 11Research spending hits $15M as Inhibikase (IKT) posts a wider Q3 loss.
NeutralNov 11
